The Effect of Three-Month Vitamin D Supplementation on the Levels of Homocysteine Metabolism Markers and Inflammatory Cytokines in Sera of Psoriatic Patients

• Published in: Biomolecules (Basel, Switzerland) Switzerland), 2021-12, Vol.11 (12), p.1865
• Main Authors: Prtina, Alma, Rašeta Simović, Nela, Milivojac, Tatjana, Vujnić, Milorad, Grabež, Milkica, Djuric, Dragan, Stojiljković, Miloš P, Soldat Stanković, Valentina, Čolić, Miodrag J, Škrbić, Ranko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers - blood; C-reactive protein; cytokine; Cytokines; Cytokines - blood; Cytokines - drug effects; Dendritic cells; Dietary Supplements; Disease; Female; Folic acid; Gene Expression Regulation - drug effects; Homocysteine; Homocysteine - blood; Homocysteine - drug effects; Humans; Hypertension; IL-1β; Immunoassay; Insulin resistance; Interferon; Interleukin 10; Interleukin 17; Interleukin 5; Interleukin 6; Interleukin 8; Lymphocytes; Male; Metabolism; Middle Aged; Nutrient deficiency; Pathogenesis; Patient Acuity; Patients; Peptides; Prospective Studies; Psoriasis; Psoriasis - blood; Psoriasis - drug therapy; Serum levels; Skin; Skin diseases; Supplements; Tumor necrosis factor-α; Values; Vitamin B; Vitamin B 12 - blood; Vitamin D; Vitamin D - administration & dosage; Vitamin D - pharmacology; Vitamin D Deficiency - blood; Vitamin D Deficiency - drug therapy; vitamin D supplementation; Vitamin deficiency
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom11121865

Psoriasis is an autoimmune and inflammatory skin disease. Psoriatic patients express higher levels of plasma homocysteine (Hcy) concentration and pro-inflammatory mediators than healthy people; this is frequently associated with vitamin D deficiency. The aim of this clinical study was to investigate the effects of high doses of vitamin D supplementation on the parameters of Hcy metabolism and cytokines in sera of psoriatic patients. This prospective study was conducted on 40 psoriatic patients who had the vitamin D deficiency. All patients received vitamin D 5000 IU/day for three months. Clinical and biochemical measurements were taken at baseline and at follow up (3 months). The results showed that the severity of clinical features, measured by the psoriasis area severity index (PASI) score, were considerably improved in patients after vitamin D supplementation. After vitamin D supplementation, most of the patients ( = 25 or 62.5%) had mild clinical form ( < 0.001). After twelve weeks of intervention period, there were significant increases in vitamin D and B serum levels in comparison to the levels that had been measured at the beginning of the study (56.77 ± 14.66 nmol/L and 301.08 ± 95.02 pg/mL vs. 103.85 ± 32.20 nmol/L and 362.81 ± 118.56 pg/mL, respectively; < 0.001). Moreover, serum levels of Hcy and folate were significantly lower at the end of the study in comparison with the initial levels (12.45 ± 1.92 µmol/L and 8.01 ± 3.88 mg/mL vs. 10.38 ± 1.66 µmol/L and 6.27 ± 2.60 mg/mL, respectively). High doses of vitamin D supplementation led to a significant decrease in pro-inflammatory cytokines (IFN-ɤ, TNF-α, IL-1β, IL-6, IL-8, and IL-17) and high-sensitivity C-reactive protein (hsCRP), whereas the production of anti-inflammatory cytokines (IL-10, IL-5) was up-regulated. In conclusion, supplementation with high doses of vitamin D could be one of the possible preventive and therapeutic measures to reduce systemic inflammation in psoriatic patients.